These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Xenovaccinotherapy for colorectal cancer. Seledtsov VI; Niza NA; Felde MA; Shishkov AA; Samarin DM; Seledtsova GV; Seledtsov DV Biomed Pharmacother; 2007; 61(2-3):125-30. PubMed ID: 17258887 [TBL] [Abstract][Full Text] [Related]
23. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies. Herd ZL Cancer Res; 1987 May; 47(10):2696-703. PubMed ID: 3552203 [TBL] [Abstract][Full Text] [Related]
24. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. Livingston PO; Calves MJ; Natoli EJ J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726 [TBL] [Abstract][Full Text] [Related]
26. Development of host immunity to phenotypically diverse B16 melanoma clones. Implications for tumor growth and metastasis. Stackpole CW; Alterman AL; Braverman S; Rappaport I Invasion Metastasis; 1987; 7(6):346-66. PubMed ID: 3436737 [TBL] [Abstract][Full Text] [Related]
27. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Björkdahl O; Dohlsten M; Sjögren HO Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695 [TBL] [Abstract][Full Text] [Related]
28. [Anti-tumor immune response against mouse melanoma to xenogeneic vaccination]. Luo F; Wei Y; Kan B Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):118-21. PubMed ID: 11783014 [TBL] [Abstract][Full Text] [Related]
29. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. Chen PW; Ksander BR Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019 [TBL] [Abstract][Full Text] [Related]
30. Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors. Baniyash M; Smorodinsky NI; Yaakubovicz M; Witz IP J Immunol; 1982 Sep; 129(3):1318-23. PubMed ID: 7108209 [TBL] [Abstract][Full Text] [Related]
31. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag. Felicetti P; Mennecozzi M; Barucca A; Montgomery S; Orlandi F; Manova K; Houghton AN; Gregor PD; Concetti A; Venanzi FM Cytotherapy; 2007; 9(1):23-34. PubMed ID: 18236207 [TBL] [Abstract][Full Text] [Related]
32. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135 [TBL] [Abstract][Full Text] [Related]
33. Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate. Ito A; Fujioka M; Tanaka K; Kobayashi T; Honda H J Biosci Bioeng; 2005 Jul; 100(1):36-42. PubMed ID: 16233848 [TBL] [Abstract][Full Text] [Related]
34. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity. Si SY; Hu PZ; Huang YY; Ye J; Huang Y; Li ZS; Ge W; Li X; Qu P; Zhang XM; Sui YF Biochem Biophys Res Commun; 2006 Aug; 347(1):208-14. PubMed ID: 16814254 [TBL] [Abstract][Full Text] [Related]
35. [Mechanism of augmented anti-tumor immunity in reconstituted lymphopenic mice immunized with melanoma vaccine]. Ma J; Wang YL; Hu HM; Fox BA; Si LS Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):708-12. PubMed ID: 16483476 [TBL] [Abstract][Full Text] [Related]
36. Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine. Johnston D; Bystryn JC J Natl Cancer Inst; 1991 Sep; 83(17):1240-5. PubMed ID: 1870150 [TBL] [Abstract][Full Text] [Related]
37. Increased tumor immunity in mice inoculated with muconomycin A-treated B16 melanoma cells. Brinckerhoff CE; Lubin M Cancer Res; 1978 Nov; 38(11 Pt 1):3668-72. PubMed ID: 698927 [TBL] [Abstract][Full Text] [Related]
38. Identification of melanoma cell surface antigens immunogenic in mice. Johnston D; el Rouby S; Bystryn JC Cancer Biother; 1994; 9(1):29-38. PubMed ID: 7812355 [TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens. Bystryn JC Ann N Y Acad Sci; 1993 Aug; 690():190-203. PubMed ID: 8368738 [No Abstract] [Full Text] [Related]
40. Clinical activity of a polyvalent melanoma antigen vaccine. Bystryn JC Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]